Sonal Admane
The University of Texas MD Anderson Cancer Center · 36 works · 10,211 citations · h-index 10
Top works
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care
- Code Status Documentation in the Outpatient Electronic Medical Records of Patients with Metastatic Cancer
- Components of early intervention outpatient palliative care consultation in patients with incurable NSCLC
- Safely Prescribing Opioids With Nirmatrelvir/Ritonavir - Case Report and Management Recommendations
- Caught in the Name Game: Navigating the Data Linkage Conundrum
- Chatbot Performance in Defining and Differentiating Palliative Care, Supportive Care, Hospice Care
- Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
- Proportional Sedation for Persistent Agitated Delirium in Palliative Care
- Nosocomial dengue in health-care workers
- Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial.
- Trends in Outpatient Opioid Prescriptions for Cancer Pain Between 2016 and 2021
- Perceptions Toward Naloxone Among Patients With Cancer Receiving Opioids
- Clinicopathologic features of EML4-ALK mutant lung cancer
- Illness understanding in patients with advanced lung cancer
- Malnutrition Risk and the Psychological Burden of Anorexia and Cachexia in Patients With Advanced Cancer
- Performance of Three Conversational Artificial Intelligence Agents in Defining End-of-Life Care Terms
- Perspectives on Self-Reported Sexual Dysfunction by Palliative Care Patients with Cancer
- Evaluation of Quality-of-life (QoL) in patients(pts) with advanced solid tumors as screening tool during phase 1 clinical trial recruitment- risk assessment for adverse events and subject replacement.